Clinical trials: Huntington's Dementia
Huntington Disease, Healthy
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
- Trial name
- MEND-HD (NCT07010705)
- Testing
- ActiGraph LEAP, Axivity AX6
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Huntington Disease
Mitochondrial Biomarkers in Huntington's Disease
The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
- Trial name
- NCT04515550
- Testing
- lumbar puncture
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Huntington Disease
Synaptic Density and Progression of Huntington's Disease.
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with HD.
- Trial name
- NCT04701580
- Testing
- 11C-UCB-J PET-CT, 18F-FDG PET-MR
- Where
- Belgium
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington Disease
MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease
The aim of this study is to assess the clinical benefit of intrastriatal grafting of human cells from the foetal ganglionic eminence in patients with Huntington's disease. The duration of the study will be 52 months.
- Trial name
- MIG-HD (NCT00190450)
- Testing
- graft intracerebral of foetal neurons
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington Disease
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
The principal means of measuring motor impairment in Huntington disease (HD) is the Unified Huntington's Disease Rating Scale (UHDRS) total motor score, which is subjective, categorical, requires significant training to…
- Trial name
- NCT03599076
- Testing
- HD Wear
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BioSensics
Huntington Disease
Benchmarking Integrated Care for People Living With Huntington's Disease in England
The survey and full study information can be accessed here: https://southampton.qualtrics.com/jfe/form/SV_8iEedDJZy4xaiI6 The goal of this anonymous survey is to benchmark integrated care from the perspective of service users in…
- Trial name
- Integrate-HD (NCT05828992)
- Testing
- No intervention administered
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Huntington Disease
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with, or at risk for, manifest Huntington's Disease (HD).
- Trial name
- NCT04514367
- Testing
- ANX005
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Annexon, Inc.
Huntington's Disease, Parkinson's Disease
Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon
The proposed study is a double-blind, placebo controlled pilot study of HD, PD, and DLB subjects with sleep disturbances. This study is designed to determine the effects of 4 weeks Ramelteon treatment on the sleep patterns of…
- Conditions
- Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders
- Trial name
- NCT00907595
- Testing
- Ramelteon
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Huntington's Disease
Study of Memantine to Treat Huntington's Disease
To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).
- Trial name
- NCT00652457
- Testing
- Memantine
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jody Corey-Bloom, MD, PhD
Huntington Disease, Deep Brain Stimulation
Deep Brain Stimulation Treatment for Chorea in Huntington's Disease
1. Evaluating therapeutic effects of globus pallidus internus (GPi) deep brain stimulation (DBS) on Huntington's disease (HD) patients with chorea； 2.
- Trial name
- NCT04244513
- Testing
- Deep brain stimulation
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Huntington Disease
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD).
- Trial name
- BioDigit HD-02 (NCT07315984)
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BioSensics
Huntington Disease
Pridopidine Phase 3 Study in Huntington's Disease
The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine.
- Trial name
- PRECISE-HD (NCT07609108)
- Testing
- Pridopidine
- Where
- 66 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- Prilenia
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer
Huntington's Disease
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites…
- Trial name
- NCT01574053
- Where
- 183 sites in United States, Argentina and 18 more
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease
Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study
The goal of this clinical trial is to investigate if new, early biomarkers of the disease are available in presymptomatic genetic carriers of Huntington\'s diesase compared to healthy subjects.
- Trial name
- BIO-MH (NCT06626308)
- Testing
- brain functional MRI
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Chorea, Huntington
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
- Trial name
- KINECT-HD (NCT04102579)
- Testing
- Valbenazine
- Where
- 46 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Neurocrine Biosciences
Huntington's Disease
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.
- Trial name
- DIMOND (NCT00497159)
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Medivation, Inc.
Huntington's Disease
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
- Trial name
- NCT00219804
- Sponsor
- Prestwick Pharmaceuticals
Huntington Disease
Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study
This trial examines whether 12 weeks of time-restricted eating (TRE), otherwise known as intermittent fasting, appears safe and feasible in persons with early-stage Huntington's disease (HD).
- Trial name
- TREHD (NCT06490367)
- Testing
- Time-Restricted Eating Diet
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Oregon Health and Science University